| scholarly article | Q13442814 |
| P50 | author | Mairéad Mcnamara | Q70853206 |
| P2093 | author name string | Warren P Mason | |
| Solmaz Sahebjam | |||
| P2860 | cites work | Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 |
| miRBase: integrating microRNA annotation and deep-sequencing data | Q24615914 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme | Q26824557 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| PTEN: life as a tumor suppressor | Q28203431 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study | Q30413713 | ||
| Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers | Q30414111 | ||
| The pathobiology of glioma tumors | Q33921072 | ||
| Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase | Q34062688 | ||
| MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma | Q34450679 | ||
| A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. | Q34534070 | ||
| Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy | Q34631627 | ||
| Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. | Q34674502 | ||
| Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers | Q34815207 | ||
| Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. | Q54378706 | ||
| 18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. | Q55461622 | ||
| Chemoresistance of glioblastoma cancer stem cells--much more complex than expected | Q35521316 | ||
| Conditional probability of survival in patients with newly diagnosed glioblastoma | Q35527367 | ||
| The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells | Q35836051 | ||
| CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays | Q36209001 | ||
| Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas | Q36236484 | ||
| A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme | Q36364358 | ||
| Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients | Q36552755 | ||
| MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. | Q36552798 | ||
| Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma | Q36560956 | ||
| ELTD1, a potential new biomarker for gliomas | Q36564447 | ||
| Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas | Q36651893 | ||
| Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies | Q36792720 | ||
| Molecular tools: biology, prognosis, and therapeutic triage | Q37779873 | ||
| Molecular diagnostics of gliomas: state of the art. | Q37780495 | ||
| Molecular diagnostics of gliomas: the clinical perspective | Q37791463 | ||
| Clinical significance of molecular biomarkers in glioblastoma | Q37808031 | ||
| Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial | Q37976320 | ||
| Molecular profiling assays in breast cancer: are we ready for prime time? | Q38015422 | ||
| MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry | Q38044236 | ||
| Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. | Q39224420 | ||
| MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. | Q39321003 | ||
| Impact of genotype and morphology on the prognosis of glioblastoma | Q39599088 | ||
| Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma | Q40188487 | ||
| A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution | Q40781380 | ||
| DNA methylation profiles of long- and short-term glioblastoma survivors | Q41386607 | ||
| Clinical implications of microRNAs in human glioblastoma | Q41872498 | ||
| Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. | Q43517288 | ||
| MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients | Q44273844 | ||
| Genetic pathways to glioblastoma: a population-based study | Q44673208 | ||
| Loss of heterozygosity on chromosome 10q in glioblastomas, and its association with other genetic alterations and survival in Indian patients | Q45276389 | ||
| The Role of Cancer Stem Cells (CD133+) in Malignant Gliomas | Q45863982 | ||
| Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma | Q46082218 | ||
| Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. | Q46118866 | ||
| The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma | Q48213191 | ||
| Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme | Q48483881 | ||
| Telomerase activity and hTERT mRNA expression in glial tumors. | Q48548441 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | glioblastoma | Q282142 |
| biomarker | Q864574 | ||
| P304 | page(s) | 1103-1119 | |
| P577 | publication date | 2013-08-22 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Emerging biomarkers in glioblastoma | |
| P478 | volume | 5 |
| Q42128435 | A Proposed Paradigm Shift in Initializing Cancer Predictive Models with DCE-MRI Based PK Parameters: A Feasibility Study |
| Q38944047 | An update on the epigenetics of glioblastomas |
| Q49023583 | Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors |
| Q44390021 | Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas. |
| Q92696929 | Artificial microenvironment of in vitro glioblastoma cell cultures changes profile of miRNAs related to tumor drug resistance |
| Q33882712 | Assessment Effects of Resveratrol on Human Telomerase Reverse Transcriptase Messenger Ribonucleic Acid Transcript in Human Glioblastoma. |
| Q47719520 | Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype |
| Q48711640 | Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas |
| Q93133145 | CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma |
| Q36082467 | Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma |
| Q37064197 | DEMARCATE: Density-based magnetic resonance image clustering for assessing tumor heterogeneity in cancer |
| Q30388310 | Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody |
| Q39601750 | ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models |
| Q27015780 | Ephs and Ephrins in malignant gliomas |
| Q38781031 | ExRNA in Biofluids as Biomarkers for Brain Tumors |
| Q89073492 | Fabrication and Characterization of Chitosan-Hyaluronic Acid Scaffolds with Varying Stiffness for Glioblastoma Cell Culture |
| Q49478610 | Failure of the PTEN/aPKC/Lgl Axis Primes Formation of Adult Brain Tumours in Drosophila |
| Q47844364 | Glioma targeting peptide in combination with the P53 C terminus inhibits glioma cell proliferation in vitro |
| Q48466686 | Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening |
| Q47333583 | In Vitro/In Silico Study on the Role of Doubling Time Heterogeneity among Primary Glioblastoma Cell Lines |
| Q45794856 | IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals |
| Q92628156 | Molecular Biomarkers of Brain and Spinal Cord Astrocytomas |
| Q38233171 | Molecular and genetic pathways in gliomas: the future of personalized therapeutics |
| Q39148751 | Molecular markers in glioma |
| Q26746028 | New perspectives in glioblastoma antiangiogenic therapy |
| Q37665446 | New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity |
| Q42426159 | Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma |
| Q92005605 | Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme |
| Q39021644 | Quantitative sodium MR imaging: A review of its evolving role in medicine |
| Q38739741 | RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells |
| Q93018161 | Radiologic image-based statistical shape analysis of brain tumours |
| Q34886810 | Role of glycosyltransferase PomGnT1 in glioblastoma progression |
| Q34668694 | Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation |
| Q52722719 | Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression. |
| Q48311392 | Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis |
| Q47830458 | Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. |
| Q33677448 | Ultra-High Mass Resolution MALDI Imaging Mass Spectrometry of Proteins and Metabolites in a Mouse Model of Glioblastoma |
| Q90596614 | miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma |
Search more.